The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Kathy Albain was named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine.

The endowed chair will enable Albain to devote more time to cancer research, and is recognition of the outstanding contributions she has made as a physician, researcher, teacher and mentor. The chair is funded by Heidi Huizenga, one of Albain’s grateful patients, her husband Peter, and her family.

Albain is a professor in the division of hematology/oncology in the department of medicine of Loyola University Chicago Stritch School of Medicine. She is director of Loyola Cardinal Bernardin Cancer Center’s breast clinical research program, co-director of the multidisciplinary breast oncology center and director of the thoracic oncology program.

Albain is a leader in national clinical trials of new treatments for breast and lung cancer as well as cancer survivorship research.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account